Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

While they share similarities, there are differences, particularly between the drugs semaglutide and tirzepatide.

Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and ...

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Ebn Sina Medical, a subsidiary of Aamal Company QPSC and a leading supplier of pharmaceutical, and Novo Nordisk, the Danish ...

Last year, more than 16 million people googled 'semaglutide' - sold under the brand names Wegovy and Ozempic - as demand for ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.